Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cancer

FDA approves rolapitant to prevent chemotherapy-induced nausea

The US Food and Drug Administration (FDA) has approved rolapitant (Varubi; Tesaro) as part of a combination of drugs to prevent nausea and vomiting caused by certain types of cancer chemotherapy. In the image, a woman receives chemotherapy

Source: Shutterstock.com

Rolapitant, a substance P/neurokinin-1 (NK-1) receptor antagonist, has been given the green light by the FDA to prevent delayed phase chemotherapy-induced nausea and vomiting

The US Food and Drug Administration (FDA) has approved rolapitant (Varubi; Tesaro) as part of a combination of drugs to prevent nausea and vomiting caused by certain types of cancer chemotherapy.

Rolapitant is a substance P/neurokinin-1 (NK-1) receptor antagonist, blocking receptors that play a central role in nausea and vomiting. Its approval to prevent delayed phase chemotherapy-induced nausea and vomiting follows three clinical trials that showed it was better than placebo at reducing nausea and vomiting in patients taking emetic chemotherapy, when combined with granisetron and dexamethasone.

The most common side effects to treatment with rolapitant include neutropenia, hiccups, decreased appetite and dizziness.

Nausea and vomiting are common side effects of cancer chemotherapy. The symptoms can begin with the first cycle of drugs, and can kick in 24–120 hours after taking the drug, known as delayed phase nausea and vomiting. As well as being unpleasant for the patient and his or her families and carers, this delayed symptom can lead to weight loss, dehydration and malnutrition, disrupting daily life, and potentially delaying further cycles of treatment.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069288

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The US Food and Drug Administration (FDA) has approved rolapitant (Varubi; Tesaro) as part of a combination of drugs to prevent nausea and vomiting caused by certain types of cancer chemotherapy. In the image, a woman receives chemotherapy

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.